Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
21.56B
Market cap21.56B
Price-Earnings ratio
-6.67
Price-Earnings ratio-6.67
Dividend yield
Dividend yield
Average volume
7.77M
Average volume7.77M
High today
$57.78
High today$57.78
Low today
$48.78
Low today$48.78
Open price
$49.00
Open price$49.00
Volume
20.93M
Volume20.93M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

Moderna(MRNA) stock is priced at $56.32, giving the company a market capitalization of 21.56B. It carries a P/E multiple of -6.67.

On 2026-05-10, Moderna(MRNA) stock moved within a range of $48.78 to $57.78. With shares now at $56.32, the stock is trading +15.5% above its intraday low and -2.5% below the session's peak.

Trading volume for Moderna(MRNA) stock has reached 20.93M, versus its average volume of 7.77M.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.

MRNA News

TipRanks 1d
Moderna’s Hantavirus Hype Fuels Rally Amid Setbacks

Moderna ( (MRNA) ) has risen by 14.90%. Read on to learn why. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, shar...

Simply Wall St 1d
Moderna Is Up 5.7% After Strong Flu Data and Completed Buyback Program - What's Changed

In the first quarter of 2026, Moderna reported revenue of US$389 million versus US$108 million a year earlier, alongside a net loss of US$1.34 billion and basic...

Moderna Is Up 5.7% After Strong Flu Data and Completed Buyback Program - What's Changed
Benzinga 2d
What's Going On With Novavax Stock On Friday?

Bloomberg noted that Moderna said it is conducting early-stage research into vaccines targeting hantaviruses, even as health experts suggest the virus linked to...

What's Going On With Novavax Stock On Friday?

Analyst ratings

65%

of 26 ratings
Buy
19.2%
Hold
65.4%
Sell
15.4%

More MRNA News

TipRanks 2d
Moderna Stock Surges 14% on Hantavirus Vaccine. Here’s What Investors Should Know

Moderna (MRNA) shares are surging 14% at the time of writing as investors react to the hantavirus and the biotech company’s early vaccine work. The virus has be...

TipRanks 2d
Moderna and Merck Halt Key mRNA Skin Cancer Trial: What Investors Should Know

Moderna (MRNA) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions D...

Benzinga 2d
Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know

Moderna stock is showing upward bias. Where is MRNA stock headed? What To Watch: Moderna’s Flu Vaccine Phase 3 Results Moderna Stock: Key Levels To Watch With p...

Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know
Simply Wall St 3d
Moderna Flu Breakthrough Puts mRNA-1010 And Valuation In Focus

Moderna published Phase 3 results for its mRNA-1010 flu vaccine in the New England Journal of Medicine. The mRNA flu vaccine showed higher efficacy compared wi...

Moderna Flu Breakthrough Puts mRNA-1010 And Valuation In Focus
Barron's 3d
Hantavirus: What to Know About the Virus—and Why Moderna Stock Rallied

Biotech and Pharma Hantavirus: What to Know About the Virus—and Why Moderna Stock Rallied In this article MRNA This aerial view shows the cruise ship MV Hondius...

Hantavirus: What to Know About the Virus—and Why Moderna Stock Rallied
Benzinga 3d
Moderna Stock Gives Back Early Gains: What's Happening?

Moderna stock is among today’s top performers. Why is MRNA stock up today? MRNA-1010 Demonstrates Superior Relative Vaccine Efficacy The company said the peer-r...

Moderna Stock Gives Back Early Gains: What's Happening?
Nasdaq 3d
Moderna Reaches Analyst Target Price

In recent trading, shares of Moderna Inc (Symbol: MRNA) have crossed above the average analyst 12-month target price of $136.15, changing hands for $141.04/shar...

Moderna Reaches Analyst Target Price

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.